
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc. is positioned for significant growth due to the substantial diagnosed patient population for its products, particularly ARIKAYCE, which is expected to generate full-year global revenues of $405M to $425M in 2025. The anticipated launch of Brensocatib in 2025 is projected to capitalize on a $8.2B peak sales opportunity, driven by strong demand from both patients and physicians in a market lacking effective treatments. Furthermore, Insmed's expansion of its sales infrastructure and potential label expansions for Arikayce and Treprostinil Palmitil Inhalation Powder bolster the company's prospects, with the existing product portfolio already yielding consistent revenue streams.
Bears say
Insmed Inc. presents several fundamental risks that contribute to a negative outlook on its stock. The company faces uncertainties related to unexpected safety events in its drug pipeline, potential failures in securing regulatory approvals, and difficulties associated with manufacturing and commercialization, all of which could hinder revenue generation and impact financial stability. Additionally, with a reported net loss of $235.5 million for 4Q24 and $913.8 million for FY24, coupled with significant ongoing R&D expenditures, Insmed may struggle to maintain operational viability without successful product launches and positive trial outcomes.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares